Vorhofflimmern bei Ionenkanal-Erkrankungen und Kardiomyopathien

Patienten mit Kardiomyopathien und kardialen Ionenkanal-Erkrankungen weisen aufgrund der strukturellen und elektrischen Veränderungen des Herzens ein signifikant erhöhtes Risiko für die Entwicklung eines Vorhofflimmerns auf. Dieser Beitrag gibt einen Überblick über die Bedeutung des Vorhofflimmerns bei Kardiomyopathien und Ionenkanal-Erkrankungen und die therapeutischen Ansätze, die von medikamentöser Behandlung bis hin zu invasiven Verfahren reichen.

Abstract

Atrial fibrillation (AF) is the most common arrhythmia among patients with cardiomyopathies and cardiac channelopathies, significantly increasing the risk of thromboembolic events and heart failure. This review aims to provide an overview on the management of AF in these populations, focusing on the integration of the “AF-CARE” concept, introduced in the 2024 ESC guidelines. AF-CARE emphasizes a comprehensive approach involving rhythm and rate control, stroke prevention, and the management of comorbidities. Given the elevated thromboembolic risk, anticoagulation decisions are guided by the specific cardiomyopathy and the CHA2DS2-VA score. Recent evidence supports rhythm control as the preferred strategy over rate control for better clinical outcomes. Continuous monitoring and individualized care are recommended to optimize long-term prognosis and quality of life in these patients.

Schlüsselwörter

Vorhofflimmern - Kanalopathien - Kardiomyopathie

Keywords

atrial fibrillation - channelopathies - cardiomyopathy

• Literatur

• 1 Arbelo E, Protonotarios A, Gimeno JR. et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023; 44: 3503-3626
• 2 Van Gelder IC, Rienstra M, Bunting KV. et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2024; 45: 3314-3414
• 3 Mizia-Stec K, Caforio ALP, Charron P. et al. Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Fail 2020; 7: 3601-3609
• 4 Charron P, Elliott PM, Gimeno JR. et al. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J 2018; 39: 1784-1793
• 5 Gimeno JR, Elliott PM, Tavazzi L. et al. Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. Eur Heart J Qual Care Clin Outcomes 2021; 7: 134-142
• 6 Fauchier L, Bisson A, Bodin A. et al. Ischemic Stroke in Patients With Hypertrophic Cardiomyopathy According to Presence or Absence of Atrial Fibrillation. Stroke 2022; 53: 497-504
• 7 Jung H, Sung JH, Yang PS. et al. Stroke Risk Stratification for Atrial Fibrillation Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2018; 72: 2409-2411
• 8 Garcia-Pavia P, Rapezzi C, Adler Y. et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021; 42: 1554-1568
• 9 Van Gelder IC, Groenveld HF, Crijns HJ. et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373
• 10 Kotecha D, Flather MD, Altman DG. et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol 2017; 69: 2885-2896
• 11 Brignole M, Pentimalli F, Palmisano P. et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 2021; 42: 4731-4739
• 12 Brignole M, Pokushalov E, Pentimalli F. et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018; 39: 3999-4008
• 13 Kirchhof P, Camm AJ, Goette A. et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med 2020; 383: 1305-1316
• 14 Freemantle N, Lafuente-Lafuente C, Mitchell S. et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 2011; 13: 329-345
• 15 Andrade JG, Wells GA, Deyell MW. et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med 2021; 384: 305-315
• 16 Sohns C, Fox H, Marrouche NF. et al. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med 2023; 389: 1380-1389
• 17 Zhao DS, Shen Y, Zhang Q. et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace 2016; 18: 508-520
• 18 Mugnai G, Hünük B, Ströker E. et al. Long-term outcome of pulmonary vein isolation in patients with paroxysmal atrial fibrillation and Brugada syndrome. Europace 2018; 20: 548-554
• 19 Kitamura T, Fukamizu S, Kawamura I. et al. Long-term efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with Brugada syndrome and an implantable cardioverter-defibrillator to prevent inappropriate shock therapy. Heart Rhythm 2016; 13: 1455-1459